Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

Exclusion Criteria

• •Complicated course of influenza and other acute respiratory viral infections
• •Treatment with antiviral drugs (antivirals, interferons and interferon inducers), drugs with immunomodulatory effects or antibiotics with systemic and local action within 7 days prior to the screening visit
• •Severe influenza or other ARVI with symptoms of cardiovascular disease, and other symptoms of infectious-toxic shock, and meningoencephalitic syndromes
• •Signs of primary viral pneumonia development (presence of two or more of the following symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness of percussion sound at symmetrical assessment of the upper and lower parts of the lungs
• •Infectious diseases within the last week prior to enrollment
• •"RRI children" (incidence of ARVI within the last 12 months is 6 times or more)
• •Asthma history
• •History of increased seizure activity
• •Severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis and also make it impossible to conduct a clinical study in the patient).
• •Cancer, HIV infection, tuberculosis, including those in history
• •Hypersensitivity to imidazolyl ethanamide pentandioic acid and/or excipients of Ingavirin product
• •Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose malabsorption, deficiency of glucose-6-phosphate dehydrogenase
• •Participation of the patient in any other clinical trial within the last 90 days prior to enrollment